TAF to Prevent HBV Reactivation in Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive
cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of
TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to
evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive
cancer patients receiving chemotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Chiayi Christian Hospital
Collaborators:
Chi Mei Medical Hospital Dalin Tzu Chi General Hospital National Taiwan University Hospital, Yun-Lin Branch St. Martin De Porress Hospital